HomeProductsDonafenib
Chemical structure of CAS 1130115-44-4

Donafenib

CAS No.1130115-44-4
MDL No.MFCD08460931
MFC21H16ClF3N4O3
MW467.80
InChI KeyMLDQJTXFUGDVEO-FIBGUPNXSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1130115-44-4
Product NameDonafenib

Associated Conditions

biliary tract neoplasm·cholangiocarcinoma·thyroid cancer·neoplasm·acute myeloid leukemia·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 39, Issue 27 • 2021
PMID: 34185551PMC: PMC8445562DOI: 10.1200/JCO.21.00163

Donafenib: First Approval.

Drugs • Vol. 81, Issue 16 • 2021
PMID: 34591285DOI: 10.1007/s40265-021-01603-0

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Cancer research • Vol. 64, Issue 19 • 2004
PMID: 15466206DOI: 10.1158/0008-5472.CAN-04-1443

Documentation

Similar Products